Table 3.

Prevalence and Risk of outcomes in chronic urticaria patients

Comorbidity	OR (95% CI)	OR sex (95% CI)	HR (95% Cl)	HR adj	HR adj stratified sex
Mastocytosis	171.0 (27.3–7086.0)		214.0 (94.6–484.7)	22.2 (8.6–57.3)	–
Female		83.7 (11.9–363.0)			12.4 (3.9–39.2)
Male		–			71.1 (8.9–568)
Anaphylaxsia	7.6 (4.6–12.5)		9.02 (5.7–14.3)	4.8 (2.7–8.4)	–
Female		5.7 (3.0–10.5)			4.4 (2.3–8.6)
Male		13.9 (5.6–36.5)			5.8 (2.1–16.3)
Hay fever	5.4 (4.7–6.3)		2.2 (1.6–3.0)	..
Female		5.8 (4.9–7.0)			..
Male		4.6 (3.4–6.1)			..
Thyroiditis	1.3 (0.7–2.6		2.0 (1.2–3.3)	1.4 (0.8–2.6)
Female					1.4 (0.8–5.6)
Male		1.5 (2.8–6.7)			<0,001
Depression	1.5 (1.3–1.7)		1.9 (1.3–2.8)	1.3 (1.1–1.6)
Female		1.4 (1.2–1.6)			1.2 (1.0–15)
Male		1.7 (1.3–2.2)			1.6 (1.2–2.2)
Psychosis	1.1 (0.8–1.4)		1.3 (0.4–4.2)	1.4 (1.0–1.9)
Female		1.1 (0.8–1.6)			1.8 (1.2–2.7)
Male		1.0 (0.6–1.5)			0.9 (0.5–1.6)
Osteoporosis	1.6 (1.3–1.9)		1.6 (1.4–1.9)	1.6 (1.4–1.9)
Female		1.5 (1.2–1.9)			1.5 (1.3–1.8)
Male		1.9 (0.9–3.6)			2.6 (1.7–3.7)
Atopic dermatitis	4.7 (3.6–6.1)		19.2 (14.8–25.0)	3.1 (2.0–4.8)
Female		4.6 (3.4–6.3)			3.0 (1.7–5.0)
Male		4.8 (2.8–7.9)			3.5 (1.5–7.9)
Rheumatoid arthritis	2.2 (1.7–2.7)		2.0 (1.6–2.5)	1.8 (1.4–2.3)
Female		2.3 (1.8–2.9)			1.9 (1.4–2.6)
Male		1.8 (1.1–2.9)			1.5 (0.9–2.6)
Lupus erythematosus	4.7 (2.4–7.4)		4.0 (2.1–7.7)	1.8 (1.4–2.3)
Female		4.7 (2.6–8.3)			1.9 (1.4–2.6)
Male		.			1.5 (0.9–2.6)
Vitiligo	5.4 (1.8–15.4)		..	..
Female		9.8 (2.8–35.2)
Male		..			..
Peptic ulcer	1.3 (1.0–1.7)		1.4 (1.0–1.8)	1.4 (1.1–1.9)
Female		1.4 (1.0–2.0)			1.7 (1.2–2.3)
Male		1.1 (0.6–1.9)			1.0 (0.6–1.8)
Diabetes mellitus	1.1 (0.9–1.4)		1.3 (1.1–1.6)	1.3 (1.1–1.6)
Female		1.1 (0.8–1.4)			1.3 (1.0–1.7)
Male		1.2 (0.9–1.7)			1.3 (1.0–1.7)